1887

Chapter 24 : Drug and Vaccine Development for the Treatment and Prevention of Urinary Tract Infections

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $15.00

Preview this chapter:
Zoom in
Zoomout

Drug and Vaccine Development for the Treatment and Prevention of Urinary Tract Infections, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555817404/9781555817398_Chap24-1.gif /docserver/preview/fulltext/10.1128/9781555817404/9781555817398_Chap24-2.gif

Abstract:

Urinary tract infections (UTI) are one of the most common bacterial infections, with roughly eleven-million cases reported in the U.S. each year that cost an estimated $5 billion annually ( ). More than one in every two women will experience at least one UTI in her lifetime, and nearly one in three women will have received antibiotic treatment for a UTI before age 24 ( ). The clinical manifestations of symptomatic UTI include infection-induced inflammation of the urethra (urethritis), urinary bladder (cystitis), and kidneys (pyelonephritis) and are diagnosed by the presence of high levels of bacteria in the urine (bacteriuria) with concomitant symptoms. Symptoms of cystitis include frequent urination, burning sensation and pain during urination (dysuria), suprapubic pain and/or lower abdominal discomfort, and cloudy and/or bloody, foul-smelling urine. Symptoms of pyelonephritis include the presence of bacteriuria and pyuria (white blood cells in the urine) that is accompanied by flank pain and fever, but may or may not include other symptoms of cystitis. The vast majority of UTI manifest as cystitis and urethritis, affecting primarily the lower urinary tract, but this can potentially lead to bacterial ascension to the kidneys and pyelonephritis, particularly in pregnant women, diabetics, and children with vesicoureteral reflux (VUR) ( ). As a result, renal scarring and loss of function is a potentially serious complication of any UTI, particularly in infants, where diagnosis of UTI may be delayed.

Citation: O’Brien V, Hannan T, Nielsen H, Hultgren S. 2017. Drug and Vaccine Development for the Treatment and Prevention of Urinary Tract Infections, p 589-646. In Mulvey M, Klumpp D, Stapleton A (ed), Urinary Tract Infections: Molecular Pathogenesis and Clinical Management, Second Edition. ASM Press, Washington, DC. doi: 10.1128/microbiolspec.UTI-0013-2012
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of Figure 1
Figure 1

Targeting UPEC virulence factors that are critical for pathogenesis. Uropathogenic (UPEC) elaborate a variety of surface structures and two-component systems that play critical roles in UTI pathogenesis. The stages of pathogenesis, as determined from animal models and clinical data, include initial bladder colonization and the IBC cycle (), the chronic bladder outcomes of quiescent intracellular-reservoir (QIR) formation () and chronic cystitis (), and ureteral ascension and pyelitis/pyelonephritis with increased risk for bacteremia/septicemia. UPEC surface structures that play a role in UTI pathogenesis include lipopolysaccharide (LPS), polysaccharide capsule, flagella, outer-membrane vesicles, pili, non-pilus adhesins, outer-membrane proteins (OMPs), toxins, secretion systems, and TonB-dependent iron-uptake receptors, including siderophore receptors. These virulence components are attractive drug and vaccine candidates.

Citation: O’Brien V, Hannan T, Nielsen H, Hultgren S. 2017. Drug and Vaccine Development for the Treatment and Prevention of Urinary Tract Infections, p 589-646. In Mulvey M, Klumpp D, Stapleton A (ed), Urinary Tract Infections: Molecular Pathogenesis and Clinical Management, Second Edition. ASM Press, Washington, DC. doi: 10.1128/microbiolspec.UTI-0013-2012
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 2
Figure 2

Models of pilus assembly in Gram-negative and Gram-positive pathogens. , Model of P pilus formation by the chaperone-usher pathway in uropathogenic . After secretion of pilus subunits into the periplasm via the general Sec machinery, periplasmic chaperones () serve as folding templates, providing a beta-sheet that enables proper folding of the pilin subunits into immunoglobulin-like domains, but in a non-conical orientation, in a mechanism called . Assembly and anchoring of the pilus occurs at an outer-membrane pore known as the usher (orange). The pilus-tip adhesin (red) is the first subunit to interact with the usher, via a preferential interaction between the tip adhesin/periplasmic-chaperone complex and the usher N-terminal-periplasmic domain (NTD, ), and this interaction initiates assembly by causing a conformational change in the usher that “unplugs” (Plug, ) the pore and displaces the tip-adhesin subunit/chaperone complex to two C-terminal-usher domains, CTD1 () and CTD2 () ( ). The next pilin subunit/chaperone complex then binds to the NTD and if it has an N-terminal extension that is able to complete the immunoglobulin fold of the preceding subunit in a canonical fashion, this provides the free energy to displace the chaperone, in a process called , and drive assembly ( ). In P pili, this occurs repeatedly, incorporating anywhere from hundreds to thousands of PapA major-pilin subunits (green) in the pilus, until PapH (brown) is incorporated into the pilus. PapH is a terminator because it is unable to undergo donor-strand exchange ( ). Small-molecule inhibitors () that disrupt pilus assembly (“pilicides”) or adhesin binding to its receptor (“pilus-adhesin antagonists”) have been identified ( ). , Model of sortase-mediated assembly of the endocarditis- and biofilm-associated pilus (Ebp pilus) in ( ). Unlike CUP pili in Gram-negative bacteria, sortase-assembled pilus subunits are covalently linked. Pilin subunits are first secreted to the outside of the cell via the general Sec machinery, and are retained in the membrane via a hydrophobic domain within their cell wall-sorting sequence. Sortase C (SrtC, ) cleaves the EbpA () LPETG sequence, resulting in an EbpA-SrtC thioacyl intermediate that is resolved by the EbpC () Lys186 nucleophile. Pilus polymerization occurs when SrtC processes the EbpC LPSTG sequence at the base of a growing, membrane-associated pilus forming a pilus-SrtC intermediate that is resolved by the Lys186 of an incoming EbpC subunit. EbpB () incorporates at the base of a pilus fiber when its Lys179 nucleophile resolves a pilus-SrtC intermediate. Sortase A (SrtA, ) processing of the EbpB LPKTN sequence leads to eventual incorporation of the mature pilus into the cell wall. Sortase inhibitors () may be useful for disrupting the virulence potential of Gram-positive uropathogens.

Citation: O’Brien V, Hannan T, Nielsen H, Hultgren S. 2017. Drug and Vaccine Development for the Treatment and Prevention of Urinary Tract Infections, p 589-646. In Mulvey M, Klumpp D, Stapleton A (ed), Urinary Tract Infections: Molecular Pathogenesis and Clinical Management, Second Edition. ASM Press, Washington, DC. doi: 10.1128/microbiolspec.UTI-0013-2012
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555817404.chap24
1. Griebling TL . 2005. Urologic diseases in America project: trends in resource use for urinary tract infections in women. J Urol 173 : 12811287.[PubMed] [CrossRef]
2. Foxman B . 2014. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am 28 : 113.[PubMed] [CrossRef]
3. Foxman B . 2002. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 113(Suppl 1A): 5S13S.[PubMed] [CrossRef]
4. Foxman B,, Barlow R,, D’Arcy H,, Gillespie B,, Sobel JD . 2000. Urinary tract infection: self-reported incidence and associated costs. Ann Epidemiol 10 : 509515.[PubMed] [CrossRef]
5. Hooton TM,, Stamm WE . 1997. Diagnosis and treatment of uncomplicated urinary tract infection. Infect Dis Clinics North Am 11 : 551581.[PubMed] [CrossRef]
6. Celik O,, Ipekci T,, Aydogdu O,, Yucel S . 2014. Current medical diagnosis and management of vesicoureteral reflux in children. Nephrourol Mon 6 : e13534. [PubMed]
7. Foxman B . 1990. Recurring urinary tract infection: incidence and risk factors. Am J Public Health 80 : 331333.[PubMed] [CrossRef]
8. Nuutinen M,, Uhari M . 2001. Recurrence and follow-up after urinary tract infection under the age of 1 year. Pediatr Nephrol 16 : 6972.[PubMed] [CrossRef]
9. Scholes D,, Hooton TM,, Roberts PL,, Stapleton AE,, Gupta K,, Stamm WE . 2000. Risk factors for recurrent urinary tract infection in young women. J Infect Dis 182 : 11771182.[PubMed] [CrossRef]
10. Hawn TR,, Scholes D,, Li SS,, Wang H,, Yang Y,, Roberts PL,, Stapleton AE,, Janer M,, Aderem A,, Stamm WE,, Zhao LP,, Hooton TM . 2009. Toll-like receptor polymorphisms and susceptibility to urinary tract infections in adult women. PLoS One 4 : e5990. [PubMed] [CrossRef]
11. Ronald A . 2002. The etiology of urinary tract infection: traditional and emerging pathogens. Am J Med 113(Suppl 1A): 14S19S.[PubMed] [CrossRef]
12. Sedor J,, Mulholland SG . 1999. Hospital-acquired urinary tract infections associated with the indwelling catheter. Urol Clin North Am 26 : 821828.[PubMed] [CrossRef]
13. Edwards JR,, Peterson KD,, Mu Y,, Banerjee S,, Allen-Bridson K,, Morrell G,, Dudeck MA,, Pollock DA,, Horan TC . 2009. National Healthcare Safety Network (NHSN) report: data summary for 2006 through 2008, issued December 2009. Am J Infect Control 37 : 783805.[PubMed] [CrossRef]
14. Hidron AI,, Edwards JR,, Patel J,, Horan TC,, Sievert DM,, Pollock DA,, Fridkin SK . 2008. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 29 : 9961011.[PubMed] [CrossRef]
15. Lo E,, Nicolle L,, Classen D,, Arias KM,, Podgorny K,, Anderson DJ,, Burstin H,, Calfee DP,, Coffin SE,, Dubberke ER,, Fraser V,, Gerding DN,, Griffin FA,, Gross P,, Kaye KS,, Klompas M,, Marschall J,, Mermel LA,, Pegues DA,, Perl TM,, Saint S,, Salgado CD,, Weinstein RA,, Wise R,, Yokoe DS . 2008. Strategies to prevent catheter-associated urinary tract infections in acute care hospitals. Infect Control Hosp Epidemiol 29(Suppl 1): S4150.[PubMed] [CrossRef]
16. Warren JW,, Damron D,, Tenney JH,, Hoopes JM,, Deforge B,, Muncie HL Jr . 1987. Fever, bacteremia, and death as complications of bacteriuria in women with long-term urethral catheters. J Infect Dis 155 : 11511158.[PubMed] [CrossRef]
17. Wagenlehner FM,, Cek M,, Naber KG,, Kiyota H,, Bjerklund-Johansen TE . 2012. Epidemiology, treatment and prevention of healthcare-associated urinary tract infections. World J Urol 30 : 5967.[PubMed] [CrossRef]
18. Raz R,, Gennesin Y,, Wasser J,, Stoler Z,, Rosenfeld S,, Rottensterich E,, Stamm WE . 2000. Recurrent urinary tract infections in postmenopausal women. Clin Infect Dis 30 : 152156.[PubMed] [CrossRef]
19. Rogers BA,, Sidjabat HE,, Paterson DL . 2011. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J Antimicrob Chemother 66 : 114.[PubMed] [CrossRef]
20. Weyrauch HM,, Rosenberg ML,, Amar AD,, Redor M . 1957. Effects of antibiotics and vaccination on experimental pyelonephritis. J Urol 78 : 532539.[PubMed]
21. van der Starre WE,, van Nieuwkoop C,, Paltansing S,, van’t Wout JW,, Groeneveld GH,, Becker MJ,, Koster T,, Wattel-Louis GH,, Delfos NM,, Ablij HC,, Leyten EM,, Blom JW,, van Dissel JT . 2010. Risk factors for fluoroquinolone-resistant Escherichia coli in adults with community-onset febrile urinary tract infection. J Antimicrob Chemother 66 : 650656.[PubMed] [CrossRef]
22. Taneja N,, Rao P,, Arora J,, Dogra A . 2008. Occurrence of ESBL & Amp-C beta-lactamases & susceptibility to newer antimicrobial agents in complicated UTI. Indian J Med Res 127 : 8588.[PubMed]
23. Nicolas-Chanoine MH,, Blanco J,, Leflon-Guibout V,, Demarty R,, Alonso MP,, Canica MM,, Park YJ,, Lavigne JP,, Pitout J,, Johnson JR . 2008. Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15. J Antimicrob Chemother 61 : 273281.[PubMed] [CrossRef]
24. Totsika M,, Beatson SA,, Sarkar S,, Phan MD,, Petty NK,, Bachmann N,, Szubert M,, Sidjabat HE,, Paterson DL,, Upton M,, Schembri MA . 2011. Insights into a multidrug resistant Escherichia coli pathogen of the globally disseminated ST131 lineage: genome analysis and virulence mechanisms. PLoS One 6 : e26578. [PubMed] [CrossRef]
25. Foxman B . 2010. The epidemiology of urinary tract infection. Nat Rev Urol 7 : 653660.[PubMed] [CrossRef]
26. Aldeyab MA,, Kearney MP,, Scott MG,, Aldiab MA,, Alahmadi YM,, Darwish Elhajji FW,, Magee FA,, McElnay JC . 2012. An evaluation of the impact of antibiotic stewardship on reducing the use of high-risk antibiotics and its effect on the incidence of Clostridium difficile infection in hospital settings. J Antimicrob Chemother doi:dks330 [pii] 10.1093/jac/dks330. [PubMed] [CrossRef]
27. Mulvey MA,, Lopez-Boado YS,, Wilson CL,, Roth R,, Parks WC,, Heuser J,, Hultgren SJ . 1998. Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli . Science 282 : 14941497.[PubMed] [CrossRef]
28. Schwartz DJ,, Chen SL,, Hultgren SJ,, Seed PC . 2011. Population dynamics and niche distribution of uropathogenic Escherichia coli during acute and chronic urinary tract infection. Infect Immun 79 : 42504259.[PubMed] [CrossRef]
29. Anderson GG,, Palermo JJ,, Schilling JD,, Roth R,, Heuser J,, Hultgren SJ . 2003. Intracellular bacterial biofilm-like pods in urinary tract infections. Science 301 : 105107.[PubMed] [CrossRef]
30. Justice SS,, Hung C,, Theriot JA,, Fletcher DA,, Anderson GG,, Footer MJ,, Hultgren SJ . 2004. Differentiation and developmental pathways of uropathogenic Escherichia coli in urinary tract pathogenesis. Proc Natl Acad Sci U S A 101 : 13331338.[PubMed] [CrossRef]
31. Rosen DA,, Hooton TM,, Stamm WE,, Humphrey PA,, Hultgren SJ . 2007. Detection of intracellular bacterial communities in human urinary tract infection. PLoS Med 4 : e329. [PubMed] [CrossRef]
32. Robino L,, Scavone P,, Araujo L,, Algorta G,, Zunino P,, Vignoli R . 2013. Detection of intracellular bacterial communities in a child with Escherichia coli recurrent urinary tract infections. Pathog Dis 68 : 7881.[PubMed] [CrossRef]
33. Robino L,, Scavone P,, Araujo L,, Algorta G,, Zunino P,, Pirez MC,, Vignoli R . 2014. Intracellular bacteria in the pathogenesis of Escherichia coli urinary tract infection in children. Clin Infect Dis 59 : e158164.[PubMed] [CrossRef]
34. Hung CS,, Dodson KW,, Hultgren SJ . 2009. A murine model of urinary tract infection. Nat Protoc 4 : 12301243.[PubMed] [CrossRef]
35. O’Brien VP,, Hannan TJ,, Schaeffer AJ,, Hultgren SJ . 2015. Are you experienced? Understanding bladder innate immunity in the context of recurrent urinary tract infection. Curr Opin Infect Dis 28 : 97105.[PubMed] [CrossRef]
36. Connell I,, Agace W,, Klemm P,, Schembri M,, Marild S,, Svanborg C . 1996. Type 1 fimbrial expression enhances Escherichia coli virulence for the urinary tract. Proc Natl Acad Sci U S A 93 : 98279832.[PubMed] [CrossRef]
37. O’Hanley P,, Lark D,, Falkow S,, Schoolnik G . 1985. Molecular basis of Escherichia coli colonization of the upper urinary tract in BALB/c mice. Gal-Gal pili immunization prevents Escherichia coli pyelonephritis in the BALB/c mouse model of human pyelonephritis. J Clin Invest 75 : 347360.[PubMed] [CrossRef]
38. Langermann S,, Mollby R,, Burlein JE,, Palaszynski SR,, Auguste CG,, DeFusco A,, Strouse R,, Schenerman MA,, Hultgren SJ,, Pinkner JS,, Winberg J,, Guldevall L,, Soderhall M,, Ishikawa K,, Normark S,, Koenig S . 2000. Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli . J Infect Dis 181 : 774778.[PubMed] [CrossRef]
39. Langermann S,, Palaszynski S,, Barnhart M,, Auguste G,, Pinkner JS,, Burlein J,, Barren P,, Koenig S,, Leath S,, Jones CH,, Hultgren SJ . 1997. Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination. Science 276 : 607611.[PubMed] [CrossRef]
40. Roberts JA,, Kaack MB,, Baskin G,, Chapman MR,, Hunstad DA,, Pinkner JS,, Hultgren SJ . 2004. Antibody responses and protection from pyelonephritis following vaccination with purified Escherichia coli PapDG protein. J Urol 171 : 16821685.[PubMed] [CrossRef]
41. Tseng CC,, Huang JJ,, Wang MC,, Wu AB,, Ko WC,, Chen WC,, Wu JJ . 2007. PapG II adhesin in the establishment and persistence of Escherichia coli infection in mouse kidneys. Kidney Int 71 : 764770.[PubMed] [CrossRef]
42. Hannan TJ,, Mysorekar IU,, Hung CS,, Isaacson-Schmid ML,, Hultgren SJ . 2010. Early severe inflammatory responses to uropathogenic E. coli predispose to chronic and recurrent urinary tract infection. PLoS Pathog 6 : e1001042. [PubMed] [CrossRef]
43. Anand M,, Wang C,, French J,, Isaacson-Schmid M,, Wall LL,, Mysorekar IU . 2012. Estrogen affects the glycosaminoglycan layer of the murine bladder. Female Pelvic Med Reconstr Surg 18 : 148152.[PubMed] [CrossRef]
44. Thumbikat P,, Waltenbaugh C,, Schaeffer AJ,, Klumpp DJ . 2006. Antigen-specific responses accelerate bacterial clearance in the bladder. J Immunol 176 : 30803086.[PubMed] [CrossRef]
45. Hannan TJ,, Roberts PL,, Riehl TE,, van der Post S,, Binkley JM,, Schwartz DJ,, Miyoshi H,, Mack M,, Schwendener RA,, Hooton TM,, Stappenbeck TS,, Hansson GC,, Stenson WF,, Colonna M,, Stapleton AE,, Hultgren SJ . 2014. Inhibition of Cyclooxygenase-2 Prevents Chronic and Recurrent Cystitis. EBioMedicine 1 : 4657.[PubMed] [CrossRef]
46. Kuehn MJ,, Ogg DJ,, Kihlberg J,, Slonim LN,, Flemmer K,, Bergfors T,, Hultgren SJ . 1993. Structural basis of pilus subunit recognition by the PapD chaperone. Science 262 : 12341241.[PubMed] [CrossRef]
47. Sauer FG,, Futterer K,, Pinkner JS,, Dodson KW,, Hultgren SJ,, Waksman G . 1999. Structural basis of chaperone function and pilus biogenesis. Science 285 : 10581061.[PubMed] [CrossRef]
48. Sauer FG,, Pinkner JS,, Waksman G,, Hultgren SJ . 2002. Chaperone priming of pilus subunits facilitates a topological transition that drives fiber formation. Cell 111 : 543551.[PubMed] [CrossRef]
49. Remaut H,, Tang C,, Henderson NS,, Pinkner JS,, Wang T,, Hultgren SJ,, Thanassi DG,, Waksman G,, Li H . 2008. Fiber formation across the bacterial outer membrane by the chaperone/usher pathway. Cell 133 : 640652.[PubMed] [CrossRef]
50. Phan G,, Remaut H,, Wang T,, Allen WJ,, Pirker KF,, Lebedev A,, Henderson NS,, Geibel S,, Volkan E,, Yan J,, Kunze MB,, Pinkner JS,, Ford B,, Kay CW,, Li H,, Hultgren SJ,, Thanassi DG,, Waksman G . 2011. Crystal structure of the FimD usher bound to its cognate FimC-FimH substrate. Nature 474 : 4953.[PubMed] [CrossRef]
51. Waksman G,, Hultgren SJ . 2009. Structural biology of the chaperone-usher pathway of pilus biogenesis. Nat Rev Microbiol 7 : 765774.[PubMed] [CrossRef]
52. Kuehn MJ,, Heuser J,, Normark S,, Hultgren SJ . 1992. P pili in uropathogenic E. coli are composite fibres with distinct fibrillar adhesive tips. Nature 356 : 252255.[PubMed] [CrossRef]
53. Brzuszkiewicz E,, Bruggemann H,, Liesegang H,, Emmerth M,, Olschlager T,, Nagy G,, Albermann K,, Wagner C,, Buchrieser C,, Emody L,, Gottschalk G,, Hacker J,, Dobrindt U . 2006. How to become a uropathogen: comparative genomic analysis of extraintestinal pathogenic Escherichia coli strains. Proc Natl Acad Sci U S A 103 : 1287912884.[PubMed] [CrossRef]
54. Chen SL,, Hung CS,, Xu J,, Reigstad CS,, Magrini V,, Sabo A,, Blasiar D,, Bieri T,, Meyer RR,, Ozersky P,, Armstrong JR,, Fulton RS,, Latreille JP,, Spieth J,, Hooton TM,, Mardis ER,, Hultgren SJ,, Gordon JI . 2006. Identification of genes subject to positive selection in uropathogenic strains of Escherichia coli: a comparative genomics approach. Proc Natl Acad Sci U S A 103 : 59775982.[PubMed] [CrossRef]
55. Welch RA,, Burland V,, Plunkett G 3rd,, Redford P,, Roesch P,, Rasko D,, Buckles EL,, Liou SR,, Boutin A,, Hackett J,, Stroud D,, Mayhew GF,, Rose DJ,, Zhou S,, Schwartz DC,, Perna NT,, Mobley HL,, Donnenberg MS,, Blattner FR . 2002. Extensive mosaic structure revealed by the complete genome sequence of uropathogenic Escherichia coli . Proc Natl Acad Sci U S A 99 : 1702017024.[PubMed] [CrossRef]
56. Hung CS,, Bouckaert J,, Hung D,, Pinkner J,, Widberg C,, DeFusco A,, Auguste CG,, Strouse R,, Langermann S,, Waksman G,, Hultgren SJ . 2002. Structural basis of tropism of Escherichia coli to the bladder during urinary tract infection. Molec Microbiol 44 : 903915.[PubMed] [CrossRef]
57. Choudhury D,, Thompson A,, Stojanoff V,, Langermann S,, Pinkner J,, Hultgren SJ,, Knight SD . 1999. X-ray structure of the FimC-FimH chaperone-adhesin complex from uropathogenic Escherichia coli . Science 285 : 10611066.[PubMed] [CrossRef]
58. Zhou G,, Mo W-J,, Sebbel P,, Min G,, Neubert TA,, Glockshuber R,, Wu X-R,, Sun T-T,, Kong X-P . 2001. Uroplakin Ia is the urothelial receptor for uropathogenic Escherichia coli: evidence from in vitro FimH binding. Journal of Cell Science 114 : 40954103.[PubMed]
59. Eto DS,, Jones TA,, Sundsbak JL,, Mulvey MA . 2007. Integrin-mediated host cell invasion by type 1-piliated uropathogenic Escherichia coli . PLoS Pathog 3 : e100. [PubMed] [CrossRef]
60. Mossman KL,, Mian MF,, Lauzon NM,, Gyles CL,, Lichty B,, Mackenzie R,, Gill N,, Ashkar AA . 2008. Cutting edge: FimH adhesin of type 1 fimbriae is a novel TLR4 ligand. J Immunol 181 : 67026706.[PubMed] [CrossRef]
61. Lund B,, Lindberg F,, Marklund BI,, Normark S . 1987. The PapG protein is the alpha-D-galactopyranosyl-(1–4)-beta-D-galactopyranose-binding adhesin of uropathogenic Escherichia coli . Proc Natl Acad Sci U S A 84 : 58985902.[PubMed] [CrossRef]
62. Lichodziejewska M,, Topley N,, Steadman R,, Mackenzie RK,, Jones KV,, Williams JD . 1989. Variable expression of P fimbriae in Escherichia coli urinary tract infection. Lancet 1 : 14141418.[CrossRef]
63. Pere A,, Nowicki B,, Saxen H,, Siitonen A,, Korhonen TK . 1987. Expression of P, type-1, and type-1C fimbriae of Escherichia coli in the urine of patients with acute urinary tract infection. J Infect Dis 156 : 567574.[PubMed] [CrossRef]
64. Kisielius PV,, Schwan WR,, Amundsen SK,, Duncan JL,, Schaeffer AJ . 1989. In vivo expression and variation of Escherichia coli type 1 and P pili in the urine of adults with acute urinary tract infections. Infect Immun 57 : 16561662.[PubMed]
65. Hultgren SJ,, Porter TN,, Schaeffer AJ,, Duncan JL . 1985. Role of type 1 pili and effects of phase variation on lower urinary tract infections produced by Escherichia coli . Infect Immun 50 : 370377.[PubMed]
66. Greene SE,, Hibbing ME,, Janetka J,, Chen SL,, Hultgren SJ . 2015. Human urine decreases function and expression of type 1 pili in uropathogenic Escherichia coli . MBio 6 : e00820. [PubMed] [CrossRef]
67. Hagberg L,, Hull R,, Hull S,, Falkow S,, Freter R,, Svanborg Eden C . 1983. Contribution of adhesion to bacterial persistence in the mouse urinary tract. Infect Immun 40 : 265272.[PubMed]
68. Abraham JM,, Freitag CS,, Clements JR,, Eisenstein BI . 1985. An invertible element of DNA controls phase variation of type 1 fimbriae of Escherichia coli . Proc Natl Acad Sci U S A 82 : 57245727.[PubMed] [CrossRef]
69. Alkan ML,, Wong L,, Silverblatt FJ . 1986. Change in degree of type 1 piliation of Escherichia coli during experimental peritonitis in the mouse. Infect Immun 54 : 549554.[PubMed]
70. Bahrani-Mougeot FK,, Buckles EL,, Lockatell CV,, Hebel JR,, Johnson DE,, Tang CM,, Donnenberg MS . 2002. Type 1 fimbriae and extracellular polysaccharides are preeminent uropathogenic Escherichia coli virulence determinants in the murine urinary tract. Mol Microbiol 45 : 10791093.[PubMed] [CrossRef]
71. Wright KJ,, Seed PC,, Hultgren SJ . 2007. Development of intracellular bacterial communities of uropathogenic Escherichia coli depends on type 1 pili. Cell Microbiol 9 : 22302241.[PubMed] [CrossRef]
72. Martinez JJ,, Mulvey MA,, Schilling JD,, Pinkner JS,, Hultgren SJ . 2000. Type 1 pilus-mediated bacterial invasion of bladder epithelial cells. EMBO J 19 : 28032812.[PubMed] [CrossRef]
73. Chen SL,, Hung CS,, Pinkner JS,, Walker JN,, Cusumano CK,, Li Z,, Bouckaert J,, Gordon JI,, Hultgren SJ . 2009. Positive selection identifies an in vivo role for FimH during urinary tract infection in addition to mannose binding. Proc Natl Acad Sci U S A 106 : 2243922444.[PubMed] [CrossRef]
74. Schembri MA,, Sokurenko EV,, Klemm P . 2000. Functional flexibility of the FimH adhesin: insights from a random mutant library. Infect Immun 68 : 26382646.[PubMed] [CrossRef]
75. Sokurenko EV,, Chesnokova V,, Dykhuizen DE,, Ofek I,, Wu XR,, Krogfelt KA,, Struve C,, Schembri MA,, Hasty DL . 1998. Pathogenic adaptation of Escherichia coli by natural variation of the FimH adhesin. Proc Natl Acad Sci U S A 95 : 89228926.[PubMed] [CrossRef]
76. Sokurenko EV,, Courtney HS,, Maslow J,, Siitonen A,, Hasty DL . 1995. Quantitative differences in adhesiveness of type 1 fimbriated Escherichia coli due to structural differences in fimH genes. J Bacteriol 177 : 36803686.[PubMed]
77. Sokurenko EV,, Courtney HS,, Ohman DE,, Klemm P,, Hasty DL . 1994. FimH family of type 1 fimbrial adhesins: functional heterogeneity due to minor sequence variations among fimH genes. J Bacteriol 176 : 748755.[PubMed]
78. Schwartz DJ,, Kalas V,, Pinkner JS,, Chen SL,, Spaulding CN,, Dodson KW,, Hultgren SJ . 2013. Positively selected FimH residues enhance virulence during urinary tract infection by altering FimH conformation. Proc Natl Acad Sci U S A 110 : 1553015537.[PubMed] [CrossRef]
79. Thumbikat P,, Berry RE,, Zhou G,, Billips BK,, Yaggie RE,, Zaichuk T,, Sun TT,, Schaeffer AJ,, Klumpp DJ . 2009. Bacteria-induced uroplakin signaling mediates bladder response to infection. PLoS Pathog 5 : e1000415. [PubMed] [CrossRef]
80. Wang H,, Min G,, Glockshuber R,, Sun TT,, Kong XP . 2009. Uropathogenic E. coli adhesin-induced host cell receptor conformational changes: implications in transmembrane signaling transduction. J Mol Biol 392 : 352361.[PubMed] [CrossRef]
81. Eto DS,, Gordon HB,, Dhakal BK,, Jones TA,, Mulvey MA . 2008. Clathrin, AP-2, and the NPXY-binding subset of alternate endocytic adaptors facilitate FimH-mediated bacterial invasion of host cells. Cell Microbiol 10 : 25532567.[PubMed] [CrossRef]
82. Duncan MJ,, Li G,, Shin JS,, Carson JL,, Abraham SN . 2004. Bacterial penetration of bladder epithelium through lipid rafts. J Biol Chem 279 : 1894418951.[PubMed] [CrossRef]
83. Dhakal BK,, Mulvey MA . 2009. Uropathogenic Escherichia coli invades host cells via an HDAC6-modulated microtubule-dependent pathway. J Biol Chem 284 : 446454.[PubMed] [CrossRef]
84. Martinez JJ,, Hultgren SJ . 2002. Requirement of Rho-family GTPases in the invasion of Type 1-piliated uropathogenic Escherichia coli . Cell Microbiol 4 : 1928.[CrossRef]
85. Song J,, Bishop BL,, Li G,, Duncan MJ,, Abraham SN . 2007. TLR4-initiated and cAMP-mediated abrogation of bacterial invasion of the bladder. Cell Host Microbe 1 : 287298.[PubMed] [CrossRef]
86. Doye A,, Mettouchi A,, Bossis G,, Clement R,, Buisson-Touati C,, Flatau G,, Gagnoux L,, Piechaczyk M,, Boquet P,, Lemichez E . 2002. CNF1 exploits the ubiquitin-proteasome machinery to restrict Rho GTPase activation for bacterial host cell invasion. Cell 111 : 553564.[PubMed] [CrossRef]
87. Rippere-Lampe KE,, O’Brien AD,, Conran R,, Lockman HA . 2001. Mutation of the gene encoding cytotoxic necrotizing factor type 1 (cnf(1)) attenuates the virulence of uropathogenic Escherichia coli . Infect Immun 69 : 39543964.[PubMed] [CrossRef]
88. Johnson DE,, Drachenberg C,, Lockatell CV,, Island MD,, Warren JW,, Donnenberg MS . 2000. The role of cytotoxic necrotizing factor-1 in colonization and tissue injury in a murine model of urinary tract infection. FEMS Immunol Med Microbiol 28 : 3741.[PubMed] [CrossRef]
89. Kallenius G,, Mollby R,, Svenson SB,, Helin I,, Hultberg H,, Cedergren B,, Winberg J . 1981. Occurrence of P-fimbriated Escherichia coli in urinary tract infections. Lancet 2 : 13691372.[PubMed] [CrossRef]
90. Winberg J . 1984. P-fimbriae, bacterial adhesion, and pyelonephritis. Arch Dis Child 59 : 180184.[PubMed] [CrossRef]
91. Norinder BS,, Koves B,, Yadav M,, Brauner A,, Svanborg C . 2011. Do Escherichia coli strains causing acute cystitis have a distinct virulence repertoire? Microb Pathog doi:S0882-4010(11)00157-4 [pii] 10.1016/j.micpath.2011.08.005. [PubMed]
92. Dodson KW,, Pinkner JS,, Rose T,, Magnusson G,, Hultgren SJ,, Waksman G . 2001. Structural basis of the interaction of the pyelonephritic E. coli adhesin to its human kidney receptor. Cell 105 : 733743.[PubMed] [CrossRef]
93. Kallenius G,, Svenson S,, Mollby R,, Cedergren B,, Hultberg H,, Winberg J . 1981. Structure of carbohydrate part of receptor on human uroepithelial cells for pyelonephritogenic Escherichia coli . Lancet 2 : 604606.[PubMed] [CrossRef]
94. Leffler H,, Lomberg H,, Gotschlich E,, Hagberg L,, Jodal U,, Korhonen T,, Samuelsson BE,, Schoolnik G,, Svanborg-Eden C . 1982. Chemical and clinical studies on the interaction of Escherichia coli with host glycolipid receptors in urinary tract infection. Scand J Infect Dis Suppl 33 : 4651.[PubMed]
95. Stapleton AE,, Stroud MR,, Hakomori SI,, Stamm WE . 1998. The globoseries glycosphingolipid sialosyl galactosyl globoside is found in urinary tract tissues and is a preferred binding receptor In vitro for uropathogenic Escherichia coli expressing pap-encoded adhesins. Infect Immun 66 : 38563861.[PubMed]
96. de Ree JM,, van den Bosch JF . 1987. Serological response to the P fimbriae of uropathogenic Escherichia coli in pyelonephritis. Infect Immun 55 : 22042207.[PubMed]
97. Kantele A,, Papunen R,, Virtanen E,, Mottonen T,, Rasanen L,, Ala-Kaila K,, Makela PH,, Arvilommi H . 1994. Antibody-secreting cells in acute urinary tract infection as indicators of local immune response. J Infect Dis 169 : 10231028.[PubMed] [CrossRef]
98. Lomberg H,, Cedergren B,, Leffler H,, Nilsson B,, Carlstrom AS,, Svanborg-Eden C . 1986. Influence of blood group on the availability of receptors for attachment of uropathogenic Escherichia coli . Infect Immun 51 : 919926.[PubMed]
99. Stapleton A,, Hooton TM,, Fennell C,, Roberts PL,, Stamm WE . 1995. Effect of secretor status on vaginal and rectal colonization with fimbriated Escherichia coli in women with and without recurrent urinary tract infection. J Infect Dis 171 : 717720.[PubMed] [CrossRef]
100. Sheinfeld J,, Schaeffer AJ,, Cordon-Cardo C,, Rogatko A,, Fair WR . 1989. Association of the Lewis blood-group phenotype with recurrent urinary tract infections in women. N Engl J Med 320 : 773777.[PubMed] [CrossRef]
101. Kinane DF,, Blackwell CC,, Brettle RP,, Weir DM,, Winstanley FP,, Elton RA . 1982. ABO blood group, secretor state, and susceptibility to recurrent urinary tract infection in women. Br Med J (Clin Res Ed) 285 : 79.[PubMed] [CrossRef]
102. Roberts JA,, Marklund BI,, Ilver D,, Haslam D,, Kaack MB,, Baskin G,, Louis M,, Mollby R,, Winberg J,, Normark S . 1994. The Gal(alpha 1-4)Gal-specific tip adhesin of Escherichia coli P-fimbriae is needed for pyelonephritis to occur in the normal urinary tract. Proc Natl Acad Sci USA 91 : 1188911893.[PubMed] [CrossRef]
103. Roberts JA,, Kaack MB,, Baskin G,, Marklund BI,, Normark S . 1997. Epitopes of the P-fimbrial adhesin of E. coli cause different urinary tract infections. J Urol 158 : 16101613.[PubMed] [CrossRef]
104. Johnson JR,, Russo TA,, Brown JJ,, Stapleton A . 1998. papG alleles of Escherichia coli strains causing first-episode or recurrent acute cystitis in adult women. J Infect Dis 177 : 97101.[PubMed] [CrossRef]
105. Winberg J,, Mollby R,, Bergstrom J,, Karlsson KA,, Leonardsson I,, Milh MA,, Teneberg S,, Haslam D,, Marklund BI,, Normark S . 1995. The PapG-adhesin at the tip of P-fimbriae provides Escherichia coli with a competitive edge in experimental bladder infections of cynomolgus monkeys. J Exp Med 182 : 16951702.[PubMed] [CrossRef]
106. Mobley HL,, Jarvis KG,, Elwood JP,, Whittle DI,, Lockatell CV,, Russell RG,, Johnson DE,, Donnenberg MS,, Warren JW . 1993. Isogenic P-fimbrial deletion mutants of pyelonephritogenic Escherichia coli: the role of alpha Gal(1-4) beta Gal binding in virulence of a wild-type strain. Mol Microbiol 10 : 143155.[PubMed] [CrossRef]
107. Xu H,, Storch T,, Yu M,, Elliott SP,, Haslam DB . 1999. Characterization of the human Forssman synthetase gene. An evolving association between glycolipid synthesis and host-microbial interactions. J Biol Chem 274 : 2939029398.[PubMed] [CrossRef]
108. Murawski IJ,, Maina RW,, Malo D,, Guay-Woodford LM,, Gros P,, Fujiwara M,, Morgan K,, Gupta IR . 2010. The C3H/HeJ inbred mouse is a model of vesico-ureteric reflux with a susceptibility locus on chromosome 12. Kidney Int 78 : 269278.[PubMed] [CrossRef]
109. Melican K,, Sandoval RM,, Kader A,, Josefsson L,, Tanner GA,, Molitoris BA,, Richter-Dahlfors A . 2011. Uropathogenic Escherichia coli P and Type 1 fimbriae act in synergy in a living host to facilitate renal colonization leading to nephron obstruction. PLoS Pathog 7 : e1001298. [PubMed] [CrossRef]
110. Korhonen TK,, Parkkinen J,, Hacker J,, Finne J,, Pere A,, Rhen M,, Holthofer H . 1986. Binding of Escherichia coli S fimbriae to human kidney epithelium. Infect Immun 54 : 322327.[PubMed]
111. Virkola R,, Westerlund B,, Holthofer H,, Parkkinen J,, Kekomaki M,, Korhonen TK . 1988. Binding characteristics of Escherichia coli adhesins in human urinary bladder. Infect Immun 56 : 26152622.[PubMed]
112. Backhed F,, Alsen B,, Roche N,, Angstrom J,, von Euler A,, Breimer ME,, Westerlund-Wikstrom B,, Teneberg S,, Richter-Dahlfors A . 2002. Identification of target tissue glycosphingolipid receptors for uropathogenic, F1C-fimbriated Escherichia coli and its role in mucosal inflammation. J Biol Chem 277 : 1819818205.[PubMed] [CrossRef]
113. Selvarangan R,, Goluszko P,, Singhal J,, Carnoy C,, Moseley S,, Hudson B,, Nowicki S,, Nowicki B . 2004. Interaction of Dr adhesin with collagen type IV is a critical step in Escherichia coli renal persistence. Infect Immun 72 : 48274835.[PubMed] [CrossRef]
114. Marre R,, Hacker J,, Henkel W,, Goebel W . 1986. Contribution of cloned virulence factors from uropathogenic Escherichia coli strains to nephropathogenicity in an experimental rat pyelonephritis model. Infect Immun 54 : 761767.[PubMed]
115. Blanco M,, Blanco JE,, Alonso MP,, Mora A,, Balsalobre C,, Munoa F,, Juarez A,, Blanco J . 1997. Detection of pap, sfa and afa adhesin-encoding operons in uropathogenic Escherichia coli strains: relationship with expression of adhesins and production of toxins. Res Microbiol 148 : 745755.[CrossRef]
116. Qin X,, Hu F,, Wu S,, Ye X,, Zhu D,, Zhang Y,, Wang M . 2013. Comparison of adhesin genes and antimicrobial susceptibilities between uropathogenic and intestinal commensal Escherichia coli strains. PLoS One 8 : e61169. [PubMed] [CrossRef]
117. Spurbeck RR,, Stapleton AE,, Johnson JR,, Walk ST,, Hooton TM,, Mobley HL . 2011. Fimbrial profiles predict virulence of uropathogenic Escherichia coli strains: contribution of ygi and yad fimbriae. Infect Immun 79 : 47534763.[PubMed] [CrossRef]
118. Vigil PD,, Alteri CJ,, Mobley HL . 2011. Identification of in vivo-induced antigens including an RTX family exoprotein required for uropathogenic Escherichia coli virulence. Infect Immun 79 : 23352344.[PubMed] [CrossRef]
119. Vigil PD,, Stapleton AE,, Johnson JR,, Hooton TM,, Hodges AP,, He Y,, Mobley HL . 2011. Presence of putative repeat-in-toxin gene tosA in Escherichia coli predicts successful colonization of the urinary tract. MBio 2 : e00066-00011. [PubMed] [CrossRef]
120. Engstrom MD,, Alteri CJ,, Mobley HL . 2014. A conserved PapB family member, TosR, regulates expression of the uropathogenic Escherichia coli RTX nonfimbrial adhesin TosA while conserved LuxR family members TosE and TosF suppress motility. Infect Immun 82 : 36443656.[PubMed] [CrossRef]
121. Vigil PD,, Wiles TJ,, Engstrom MD,, Prasov L,, Mulvey MA,, Mobley HL . 2012. The repeat-in-toxin family member TosA mediates adherence of uropathogenic Escherichia coli and survival during bacteremia. Infect Immun 80 : 493505.[PubMed] [CrossRef]
122. Nesta B,, Spraggon G,, Alteri C,, Moriel DG,, Rosini R,, Veggi D,, Smith S,, Bertoldi I,, Pastorello I,, Ferlenghi I,, Fontana MR,, Frankel G,, Mobley HL,, Rappuoli R,, Pizza M,, Serino L,, Soriani M . 2012. FdeC, a novel broadly conserved Escherichia coli adhesin eliciting protection against urinary tract infections. MBio 3. [PubMed] [CrossRef]
123. Johnson JR,, Jelacic S,, Schoening LM,, Clabots C,, Shaikh N,, Mobley HL,, Tarr PI . 2005. The IrgA homologue adhesin Iha is an Escherichia coli virulence factor in murine urinary tract infection. Infect Immun 73 : 965971.[PubMed] [CrossRef]
124. Bishop BL,, Duncan MJ,, Song J,, Li G,, Zaas D,, Abraham SN . 2007. Cyclic AMP-regulated exocytosis of Escherichia coli from infected bladder epithelial cells. Nat Med 13 : 625630.[PubMed] [CrossRef]
125. Song J,, Bishop BL,, Li G,, Grady R,, Stapleton A,, Abraham SN . 2009. TLR4-mediated expulsion of bacteria from infected bladder epithelial cells. Proc Natl Acad Sci U S A 106 : 1496614971.[PubMed] [CrossRef]
126. Mulvey MA,, Schilling JD,, Hultgren SJ . 2001. Establishment of a persistent Escherichia coli reservoir during the acute phase of a bladder infection. Infect Immun 69 : 45724579.[PubMed] [CrossRef]
127. Wei Y,, Li K,, Wang N,, Cai GD,, Zhang T,, Lin Y,, Gui BS,, Liu EQ,, Li ZF,, Zhou W . 2015. Activation of endogenous anti-inflammatory mediator cyclic AMP attenuates acute pyelonephritis in mice induced by uropathogenic Escherichia coli . Am J Pathol 185 : 472484.[PubMed] [CrossRef]
128. Schilling JD,, Mulvey MA,, Vincent CD,, Lorenz RG,, Hultgren SJ . 2001. Bacterial invasion augments epithelial cytokine responses to Escherichia coli through a lipopolysaccharide-dependent mechanism. J Immunol 166 : 11481155.[PubMed] [CrossRef]
129. Wang C,, Mendonsa GR,, Symington JW,, Zhang Q,, Cadwell K,, Virgin HW,, Mysorekar IU . 2012. Atg16L1 deficiency confers protection from uropathogenic Escherichia coli infection in vivo. Proc Natl Acad Sci U S A 109 : 1100811013.[PubMed] [CrossRef]
130. Li B,, Smith P,, Horvath DJ Jr,, Romesberg FE,, Justice SS . 2010. SOS regulatory elements are essential for UPEC pathogenesis. Microbes Infect 12 : 662668.[PubMed] [CrossRef]
131. Blango MG,, Mulvey MA . 2010. Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics. Antimicrob Agents Chemother 54 : 18551863.[PubMed] [CrossRef]
132. Wieser A,, Guggenberger C,, Pritsch M,, Heesemann J,, Schubert S . 2011. A novel ex vivo set-up for dynamic long-term characterization of processes on mucosal interfaces by confocal imaging and simultaneous cytokine measurements. Cell Microbiol 13 : 742751.[PubMed] [CrossRef]
133. Eto DS,, Sundsbak JL,, Mulvey MA . 2006. Actin-gated intracellular growth and resurgence of uropathogenic Escherichia coli . Cell Microbiol 8 : 704717.[PubMed] [CrossRef]
134. Berry RE,, Klumpp DJ,, Schaeffer AJ . 2009. Urothelial cultures support intracellular bacterial community formation by uropathogenic Escherichia coli . Infect Immun 77 : 27622772.[PubMed] [CrossRef]
135. Reigstad CS,, Hultgren SJ,, Gordon JI . 2007. Functional genomic studies of uropathogenic Escherichia coli and host urothelial cells when intracellular bacterial communities are assembled. J Biol Chem 282 : 2125921267.[PubMed] [CrossRef]
136. Hannan TJ,, Mysorekar IU,, Chen SL,, Walker JN,, Jones JM,, Pinkner JS,, Hultgren SJ,, Seed PC . 2008. LeuX tRNA-dependent and -independent mechanisms of Escherichia coli pathogenesis in acute cystitis. Mol Microbiol 67 : 116128.[PubMed]
137. Justice SS,, Lauer SR,, Hultgren SJ,, Hunstad DA . 2006. Maturation of intracellular Escherichia coli communities requires SurA. Infect Immun 74 : 47934800.[PubMed] [CrossRef]
138. Cusumano CK,, Hung CS,, Chen SL,, Hultgren SJ . 2010. Virulence plasmid harbored by uropathogenic Escherichia coli functions in acute stages of pathogenesis. Infect Immun 78 : 14571467.[PubMed] [CrossRef]
139. Rosen DA,, Pinkner JS,, Walker JN,, Elam JS,, Jones JM,, Hultgren SJ . 2008. Molecular variations in Klebsiella pneumoniae and Escherichia coli FimH affect function and pathogenesis in the urinary tract. Infect Immun 76 : 33463356.[PubMed] [CrossRef]
140. Cegelski L,, Marshall GR,, Eldridge GR,, Hultgren SJ . 2008. The biology and future prospects of antivirulence therapies. Natl Rev Microbiol 6 : 1727.[PubMed] [CrossRef]
141. Monack DM,, Mueller A,, Falkow S . 2004. Persistent bacterial infections: the interface of the pathogen and the host immune system. Natl Rev Microbiol 2 : 747765.[PubMed] [CrossRef]
142. Anderson GG,, Goller CC,, Justice S,, Hultgren SJ,, Seed PC . 2010. Polysaccharide capsule and sialic acid-mediated regulation promote biofilm-like intracellular bacterial communities during cystitis. Infect Immun 78 : 963975.[PubMed] [CrossRef]
143. Buckles EL,, Wang X,, Lane MC,, Lockatell CV,, Johnson DE,, Rasko DA,, Mobley HL,